Following its own evaluation of the safety and toxicology of AlaskOmega 50% and 70% omega-7 concentrates, the U.S. Food and Drug Administration does not dispute the GRAS status of the ingredient.
Epax will be investing $35 million over the next two years to increase its capacity and innovate in the omega-3 sector.
Results of the recently published Omega-3 to Reduce the Incidence of Preterm Birth (ORIP) trial showed that supplementation with omega-3 long chain polyunsaturated fatty acids did not lower risk of early preterm delivery. This is leading the researchers to believe a more targeted approach may be necessary.
Bioriginal is launching a new algae-based omega-3 DHA ingredient in Europe called AlgalPure DHA.
Even in the face of an equivocal study or two—or concerns over sourcing, regulatory setbacks, and the occasional pharma-driven lawsuit—omega-3s retain a sterling reputation that other supplements can only envy.
The equation the researchers devised might make it possible to determine how much omega-3 EPA and DHA is needed to elevate the omega-3 index to the desired level.
Amarin Pharma has filed a petition for certiorari asking the Supreme Court to review a decision made by the U.S. Court of Appeals for the Federal Circuit to uphold a 2017 decision of the International Trade Commission (ITC) not to investigate Amarin’s complaints against manufacturers of omega-3 EPA concentrates.
The United States Patent and Trademark Office granted the Aker BioMarine's patent application 15/040,330, which covers Aker’s Flexitech technology, used to make Superba 2 and Superba Boost krill oil products at its Houston facility.
Synthetic ingredients’ regulatory uncertainty still a huge problem for dietary supplements, whether in Amarin’s omega-3 drug battle or in NDI guidance
Amarin Pharma’s recent comments advising FDA not to allow synthetic omega-3 supplements to be dietary supplements is just one more case in which synthetic supplement ingredients are under fire.
In comments submitted to FDA, Amarin Pharma, maker of the omega-3 drug Vascepa, stated its intentions to file a citizen petition to FDA asserting that ethyl ester omega-3s are not legally allowed to be marketed as dietary supplements.